Table 3.
Comparison of baseline characteristics between participants of the Nolan Study with plasma p-tau181 assessment (included in the present study) and participants not included
| Total n = 362 | Included n = 289 | Excluded n = 73 | p-value | |
|---|---|---|---|---|
| mean (SD)* | mean (SD)* | mean (SD)* | ||
| Treatment group | 0.938a | |||
| Nutritional blend | 180 (49.7%) | 144 (49.8%) | 36 (49.3%) | |
| Placebo | 182 (50.3%) | 145 (50.2%) | 37 (50.7%) | |
| Sex (female) | 212 (58.6%) | 163 (56.4%) | 49 (67.1%) | 0.097a |
| Age (years) | 78.3 (4.8) | 78.1 (4.7) | 79.0 (5.1) | 0.168b |
| Education (n = 361) | 0.295a | |||
| ≤ 7 years | 32 (8.9%) | 24 (8.3%) | 8 (11.0%) | |
| 8 to 9 years | 61 (16.9%) | 45 (15.6%) | 16 (21.9%) | |
| ≥10 years | 268 (74.2%) | 219 (76.0%) | 49 (67.1%) | |
| Body mass index (kg/m2) | 26.1 (4.0) | 26.2 (4.0) | 25.8 (4.2) | 0.367b |
| APOE ε4 status (n = 341) | 0.734a | |||
| ε4 carrier | 83 (24.3%) | 68 (24.7%) | 15 (22.7%) | |
| ε4 non-carrier | 258 (75.7%) | 207 (75.3%) | 51 (77.3%) | |
| CDR score | 0.060a | |||
| 0 | 144 (39.8%) | 122 (42.2%) | 22 (30.1%) | |
| 0.5 | 218 (60.2%) | 167 (57.8%) | 51 (69.9%) | |
APOE, apolipoprotein E gene; CDR, Clinical Dementia Rating; SD, standard deviation; *Except where indicated other. a Chi-Square test; b Equal variance two sample t-test.